Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Medicare Coverage Policy Pending, Blue Cross Finds Fault With ProDisc

This article was originally published in The Gray Sheet

Executive Summary

A recent negative assessment of lumbar artificial disc replacement by Blue Cross Blue Shield could spell trouble for Synthes as it seeks full Medicare coverage for ProDisc
Advertisement

Related Content

Long-Term Evidence On Artificial Cervical Discs Found Lacking By Blues' TEC
Long-Term Evidence On Artificial Cervical Discs Found Lacking By Blues' TEC
CMS Extends Non-Coverage Policy To All Artificial Lumbar Discs
CMS Extends Non-Coverage Policy To All Artificial Lumbar Discs
CMS Backs Away From Expanding Carotid Stenting Coverage
CMS Opens National Coverage Decision For Synthes’ Lumbar Disc
CMS Opens National Coverage Decision For Synthes’ Lumbar Disc
CMS Charité Policy Leaves Coverage Option Open For Under-60 Crowd
Cytyc Pays 10-Times Sales For Proxima, Breast Cancer Therapy Market Entry
Advertisement
UsernamePublicRestriction

Register

MT024831

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel